View in EDS

BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer.

Saved in:
Bibliographic Details
Title: BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer.
Authors: Wang LY; School of Materials Science and Engineering, Zhejiang University, Hangzhou, 310058, China.; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China., Xu XH; School of Materials Science and Engineering, Zhejiang University, Hangzhou, 310058, China.; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China., Xuan WJ; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China., Bi XY; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.; School of Science, Westlake University, Hangzhou, 310030, China., Zhou Q; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China. zhouqin@westlake.edu.cn.; School of Medicine, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.
Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Mar 24. Date of Electronic Publication: 2026 Mar 24.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41876745
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+LY%22">Wang LY</searchLink>; School of Materials Science and Engineering, Zhejiang University, Hangzhou, 310058, China.; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.<br /><searchLink fieldCode="AU" term="%22Xu+XH%22">Xu XH</searchLink>; School of Materials Science and Engineering, Zhejiang University, Hangzhou, 310058, China.; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.<br /><searchLink fieldCode="AU" term="%22Xuan+WJ%22">Xuan WJ</searchLink>; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.<br /><searchLink fieldCode="AU" term="%22Bi+XY%22">Bi XY</searchLink>; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China.; School of Science, Westlake University, Hangzhou, 310030, China.<br /><searchLink fieldCode="AU" term="%22Zhou+Q%22">Zhou Q</searchLink>; Research Centre for Industries of the Future, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.; Department of Materials Science and Engineering, School of Engineering, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.; Institute of Advanced Technology, Westlake Institute for Advanced Study, Hangzhou, 310024, China. zhouqin@westlake.edu.cn.; School of Medicine, Westlake University, Hangzhou, 310030, China. zhouqin@westlake.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100956087%22">Acta pharmacologica Sinica</searchLink> [Acta Pharmacol Sin] 2026 Mar 24. <i>Date of Electronic Publication: </i>2026 Mar 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Group%22">Nature Publishing Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100956087 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1745-7254 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216714083%22">16714083 </searchLink><i>NLM ISO Abbreviation: </i>Acta Pharmacol Sin <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41876745
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41401-026-01788-8
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang LY
      – PersonEntity:
          Name:
            NameFull: Xu XH
      – PersonEntity:
          Name:
            NameFull: Xuan WJ
      – PersonEntity:
          Name:
            NameFull: Bi XY
      – PersonEntity:
          Name:
            NameFull: Zhou Q
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 03
              Text: 2026 Mar 24
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1745-7254
          Titles:
            – TitleFull: Acta pharmacologica Sinica
              Type: main
ResultId 1